The Power of Vision and Strategy: Georg Schroeckenfuchs at Novartis MEA

With more than three decades of experience, Schroeckenfuchs has led the charge for Novartis Middle East and Africa (MEA), but his work has seen the company grow exponentially through innovations. Under his leadership, Novartis has outperformed market expectations but has also introduced transformative therapies to the region, revolutionizing healthcare accessibility and innovation. His passion for cell and gene therapy with sustainable growth has led Novartis MEA to become a trendsetter in the pharmaceutical industry.

Georg Schroeckenfuchs is now the head of Novartis MEA with over 30 years of pharmaceutical experience. He took over the position of President and Cluster Head and has been at the helm of the strategic growth of the company across this complex and diverse region. An extended scope that now encompasses South Africa has made Novartis MEA an indispensable hub for innovation and patient care under Schroeckenfuchs’s stewardship.

Novartis MEA has shown a remarkable growth of 6.2% in the first half of 2020 compared to the previous year, even when the global pandemic posed huge challenges. It has outstripped the market by miles since the latter expanded by just 2% in the same period. It is Schroeckenfuchs’ leadership that has been attracting investments, facilitating innovation, and driving strategic initiatives, which have kept Novartis thriving within a highly competitive market.

One of the most outstanding novelties during Schroeckenfuchs’ leadership includes Novartis’ promise of accelerating cell and gene therapy in the MEA region. The company has taken huge steps towards the actualization of advanced therapies to patients, especially rare diseases treatment. For example, Novartis has launched pioneering therapy for inherited blindness in children now available in the UAE and Saudi Arabia. It therefore demonstrates the company’s pledge to change lives with some of the latest medical innovations.

Schroeckenfuchs’ vision expands beyond financial growth to innovation and patient-centric care. The company has been a leader in the launch of innovative treatments that address unmet medical needs in the region. From oncology to ophthalmology, the company continues to expand its portfolio, providing life-changing therapies. Collaboration with local governments and healthcare institutions is also something that Schroeckenfuchs is focusing on to ensure access to these therapies for as many patients as possible.

Under Schroeckenfuchs, Novartis strengthened its regional presence through strategic partnerships and investment in local health ecosystems. It involves collaborating with healthcare authorities to improve the health infrastructure, develop, and innovate. It is through these collaborations that Novartis contributes to sustainable healthcare system development across MEA.

Georg Schroeckenfuchs is not just concerned with immediate goals; he is also building the health care of the future in the MEA region. His strategic vision involves the integration of digital health technologies and sustainability within Novartis’ operations. The firm also plans to continue its expansion in the region as it seeks to maintain its quality innovative health care products.

Clearly, industry recognition follows. His ability to grow the business whilst truly caring for patients has not gone unnoticed within the industry. Being a leader who understands business but is deeply understanding of healthcare, Schroeckenfuchs is setting new standards for pharmaceutical leadership in MEA.